Indian pharmaceutical company Biocon forecasts a stronger second half of fiscal 2027 as its latest biosimilar and generic launches in the US begin to impact sales, supported by regulatory wins and new product approvals.
Biocon said it expects a much stronger second half of fiscal 2027 as newly launched biosimilars and generic medicines in the United States begin to feed through to sales, with Chief Executive and Managing Director Shreehas Tambe saying the company sees a notable improvement versus the first half. The Indian drugmaker has rolled out five products in the U.S. market recently, giving it fresh momentum in one of its most important overseas businesses.
The newest additions include the aflibercept biosimilar Yesafili, denosumab biosimilars Bosaya and Aukelso, and generic liraglutide. Biocon has also indicated that liraglutide could benefit from more favourable U.S. regulatory conditions, which it believes should help lift revenue in the coming quarters.
Bosaya and Aukelso were commercially launched in the U.S. after approval by the Food and Drug Administration in September 2025 with interchangeable status, meaning pharmacists can substitute them for the reference products under applicable state rules. Biocon said the drugs are now available nationwide through specialty pharmacies and healthcare providers, and it has framed the products as part of a broader push into therapies for osteoporosis and bone metastasis. In a separate development, the company also said clinical data supporting Yesafili had been published in a peer-reviewed journal, reinforcing its case for the ophthalmology biosimilar.
The upbeat outlook follows a 10% rise in consolidated revenue to ₹4,336 crore for the quarter ended June 2026, compared with a year earlier. Biocon said the increase reflected steady performance across its businesses, while the latest launches are expected to become more visible in the second half of the year. The company has also received Health Canada approval for Bosaya and another denosumab biosimilar, Vevzuo, suggesting its biosimilar expansion is advancing beyond the U.S. as well.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
